Abstract:Ana Cepero, 1– 3, &ast Mónica Jiménez-Carretero, 4, &ast Ylenia Jabalera, 4 Lidia Gago, 1– 3 Cristina Luque, 1– 3 Laura Cabeza, 1– 3 Consolación Melguizo, 1– 3 Concepcion Jimenez-Lopez, 4 José Prados 1– 3 1 Institute of Biopathology and Regenerative Medicine (IBIMER), Center of Biomedical Research (CIBM), University of Granada, Granada, 18100, Spain; 2 Department of Anatomy and Embryology, Faculty of Medicine, University of Granada, Granada, 18071, Spain; 3 Biosanitary Research Institute ibs.GRANADA, Granada, 18012, Spain; 4 Department of Microbiology, Sciences School, University of Granada, Granada, 18002, Spain &astThese authors contributed equally to this work Correspondence: Laura Cabeza; Concepción Jimenez-Lopez, Email ; Purpose: The lack of specificity of conventional chemotherapy is one of the main difficulties to be solved in cancer therapy. Biomimetic magnetoliposomes are successful chemotherapy controlled-release systems, hyperthermia, and active targeting agents by functionalization of their surface with monoclonal antibodies. The membrane receptor Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) stands out as colorectal cancer (CRC) biomarker and appears to be related to treatment resistance and the development of metastasis. The aim of this study was to assess the effectiveness and safety of LGR5-targeted biomimetic magnetoliposomes loaded with oxaliplatin (OXA) or 5-fluorouracil (5-FU) in the selective treatment of CRC and their possible application in hyperthermia. Methods: Synthesis, characterization and determination of heating capacity of magnetoliposomes transporting OXA or 5-FU (with and without LGR5 functionalization) were conducted. In vitro antitumoral activity was assayed in multiple colorectal cell lines at different times of exposition. In addition to this, cell internalization was studied by Prussian Blue staining, flow cytometry and fluorescence microscopy. In vivo acute toxicity of magnetoliposomes was performed to evaluate iron-related toxicity. Results: OXA and 5-FU loaded magnetoliposomes functionalized with LGR5 antibody showed higher cellular uptake than non-targeted nanoformulation with a reduction of the percentage of proliferation in colon cancer cell lines up to 3.2-fold of the IC 50 value compared to that of free drug. The differences between non-targeted and targeted nanoformulations were more evident after short exposure times (4 and 8 hours). Interestingly, assays in the MC38 transduced cells with reduced LGR5 expression (MC38-L(-)), showed lower cell internalization of LGR5-targeted magnetoliposomes compared to non-transduced MC38 cell line. In addition, magnetoliposomes showed an in vitro favorable heating response under magnetic excitation and great iron-related biocompatibility data in vivo. Conclusion: Drug-loaded magnetoliposomes functionalized with anti-LGR5 antibodies could be a promising CRC treatment strategy for LGR5+ targeted chemotherapy, magnetic hyperthermia, and both in combination. Keywords: colorectal neoplasms, magnetoliposome, LGR5, oxaliplatin, 5-fluorouracil, magnetic hyperthermia Graphical Conventional chemotherapy usually involves the administration of drugs with side effects outside the target tissue partly because of their lack of specificity, which leads to discontinuing pharmacological treatment and limits therapeutic success. Some of the chemotherapeutic drugs most used in the treatment of colorectal cancer (CRC), the third with the highest incidence worldwide, are oxaliplatin (OXA) and 5-fluorouracil (5-FU) usually used in combinations such as FOLFOX (5-FU/leucovorin + OXA), FOLFIRI (5-FU/leucovorin + irinotecan) and FOLFIRINOX (5-FU/leucovorin + OXA + irinotecan). 1,2 The most frequent adverse effects observed were peripheral sensory neuropathy, gastrointestinal disorders and hematological suppression following the administration of OXA, and cardiotoxicity and myelosuppression after 5-FU treatment. 3–5 For this reason, the development of a new strategy of targeted therapy to the tumor tissue would allow improvement in patient's quality of life and greater adherence to treatment. Nanomedicine could be one of these new strategies because they can overcome pharmacokinetic limitations of antitumor drugs. An important factor is the low bioavailability of chemotherapeutics caused by the electronegative surface of most of them that could be solved by their encapsulation in a nanoparticle. 6 In addition, nanomedicine-based drug delivery systems permit to slow down the clearance of drugs, increase the half-life, pr -Abstract Truncated-

Anti-Tumor Efficacy of Oleuropein-Loaded ZnO/Au Mesoporous Silica Nanoparticle in 5-FU-Resistant Colorectal Cancer Cells

Chemoresistant Colorectal Cancer Cells, the Cancer Stem Cell Phenotype, and Increased Sensitivity to Insulin-like Growth Factor-I Receptor Inhibition

Luteolin Sensitizes Two Oxaliplatin-Resistant Colorectal Cancer Cell Lines to Chemotherapeutic Drugs Via Inhibition of the Nrf2 Pathway

Fe-MOF Nanoplatform: Specifically Overcoming Oxaliplatin Resistance in Colorectal Cancer Through Multifaceted Pathways

ZEB1 Promotes Oxaliplatin Resistance Through the Induction of Epithelial - Mesenchymal Transition in Colon Cancer Cells

Oxaliplatin-incorporated Micelles Eliminate Both Cancer Stem-Like and Bulk Cell Populations in Colorectal Cancer

5-Fluorouracil Nanoparticles Inhibit Hepatocellular Carcinoma Via Activation of the P53 Pathway in the Orthotopic Transplant Mouse Model

Abstract 478: Targeted combination nano-drug delivery system to enhance anti-cancer efficacy and reduce side effects

Amphiphilic Polymeric Nanodrug Integrated with Superparamagnetic Iron Oxide Nanoparticles for Synergistic Antibacterial and Antitumor Therapy of Colorectal Cancer

Colon-Targeted Sustained-Release Combinatorial 5-Fluorouracil and Quercetin poly(lactic- co-glycolic) Acid (PLGA) Nanoparticles Show Enhanced Apoptosis and Minimal Tumor Drug Resistance for Their Potential Use in Colon Cancer

Zinc oxide nanoparticle attenuates chemotherapy resistance by inducing cell stemness progression of colorectal cancer via miR-1321/HIF-2α axis

Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment

Ursolic Acid Enhances the Therapeutic Effects of Oxaliplatin in Colorectal Cancer by Inhibition of Drug Resistance

In vitro and in vivo combinatorial anticancer effects of oxaliplatin- and resveratrol-loaded N,O-carboxymethyl chitosan nanoparticles against colorectal cancer

LGR5 as a Therapeutic Target of Antibody-Functionalized Biomimetic Magnetoliposomes for Colon Cancer Therapy

Targeted co-delivery of rapamycin and oxaliplatin by liposomes suppresses tumor growth and metastasis of colorectal cancer

Oleanolic Acid Inhibits Colon Cancer Cell Stemness and Reverses Chemoresistance by Suppressing JAK2/STAT3 Signaling Pathway

Ursolic Acid Synergistically Enhances the Therapeutic Effects of Oxaliplatin in Colorectal Cancer

Modified mesoporous silica nanocarriers containing superparamagnetic iron oxide nanoparticle, 5-fluorouracil or oxaliplatin, and metformin as a radiosensitizer, significantly impact colorectal cancer radiation therapy

Abstract A066: The cytotoxic effects of oxaliplatin and 5-fluorouracil against low-grade serous ovarian cancer cells

Innovative Strategies to Combat 5-Fluorouracil Resistance in Colorectal Cancer: The Role of Phytochemicals and Extracellular Vesicles